REG - Diaceutics PLC - Notice of AGM and Posting of Annual Report

DiaceuticsAnnouncement

Yesterday 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU3740Ja&default-theme=true

RNS Number : 3740J  Diaceutics PLC  21 May 2025

Diaceutics PLC

 

Notice of AGM and Posting of Annual Report

 

New York, Belfast and London, 21 May 2025 - Diaceutics PLC (AIM: DXRX), a
leading technology and solutions provider to the pharma and biotech industry,
announces that it will today post its Annual Report for the year ended 31
December 2024 to shareholders together with the Notice of the 2025 Annual
General Meeting ("AGM").

 

The Company will hold its AGM on Wednesday, 18 June 2025 at 10.30am at First
Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park,
Belfast, County Antrim BT9 6GW.

 

The Annual Report and Notice of AGM will also be available shortly on the
Company's website at  www.diaceutics.com

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGUGDUIBDDGUG